Summary:
Comparing the efficacy, safety, and tolerability of fremanezumab vs placebo for the preventive treatment of chronic migraine in patients 6 to 17 years of age.
The investigational study drug and study procedures are provided at no charge.
Qualified Participants Must:
• Be ages 6 to 17 years old
•
Have had migraine for at least 6 months
•
Weigh at least 37.5lbs/17 kg
Qualified Participants May Receive:
Compensation for time & travel